

1 **Predicting mortality due to SARS-CoV-2: A mechanistic score** 2 **relating obesity and diabetes to COVID-19 outcomes in Mexico**

3 Omar Yaxmehen Bello-Chavolla^{1,2*}, Jessica Paola Bahena-López³, Neftali Eduardo Antonio-
4 Villa^{1,3}, Arsenio Vargas-Vázquez^{1,3}, Armando González-Díaz⁴, Alejandro Márquez-Salinas^{2,3},
5 Carlos A. Fermín-Martínez^{1,3}, J. Jesús Naveja⁵, Carlos A. Aguilar-Salinas^{1,6,7}

6 ¹Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias
7 Médicas y Nutrición Salvador Zubirán. ²Division of Research, Instituto Nacional de Geriatria.
8 ³MD/PhD (PECEM), Faculty of Medicine, National Autonomous University of Mexico.
9 ⁴Universidad Nacional Autónoma de México. ⁵Instituto de Química, Universidad Nacional
10 Autónoma de México. ⁶Department of Endocrinology and Metabolism. Instituto Nacional de
11 Ciencias Médicas y Nutrición Salvador Zubirán. ⁷Tecnologico de Monterrey, Escuela de
12 Medicina y Ciencias de la Salud.

13 **Short title:** COVID-19 mortality, diabetes and obesity in Mexico

14 **Corresponding authors**

15 Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional Geriatria. Anillo
16 Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City, Mexico.
17 Phone: +52 (55) 5548486885. E-mail: oyaxbell@yahoo.com.mx

18 Carlos A. Aguilar-Salinas. Unidad de Investigación de Enfermedades Metabólicas. Instituto
19 Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Vasco de Quiroga 15. CP
20 14080; Tlalpan, Distrito Federal, México. Phone: +52(55)54870900, 5703. E-mail:
21 caguilersalinas@yahoo.com

22 **CONFLICT OF INTERESTS:** Nothing to disclose.

23 **FUNDING:** This research received no specific funding

24 **ABSTRACT (250 WORDS)**

25 **BACKGROUND:** The SARS-CoV-2 outbreak poses challenge to healthcare systems due to
26 high complication rates in patients with cardiometabolic diseases. Here, we identify risk
27 factors and propose a clinical score to predict COVID-19 lethality, including specific factors
28 for diabetes and obesity and its role in improving risk prediction.

29 **METHODS:** We obtained data of confirmed and negative COVID-19 cases and their
30 demographic and health characteristics from the General Directorate of Epidemiology of
31 Mexican Ministry of Health. We investigated specific risk factors associated to COVID-19
32 positivity and mortality and explored the impact of diabetes and obesity on modifying COVID-
33 19 related lethality. Finally, we built a clinical score to predict COVID-19 lethality.

34 **RESULTS:** Among 71,103 subjects at April 27th, 2020, we observed 15,529 subjects with
35 SARS-CoV-2 and 1,434 deaths. Risk factors for lethality in COVID-19 includes early-onset
36 diabetes obesity, COPD, advanced age, immunosuppression, and CKD; we observed that
37 obesity mediates 45.5% of the effect of diabetes on COVID-19 lethality. Early-onset diabetes
38 conferred an increased risk of hospitalization and obesity conferred an increased risk for ICU
39 admission and intubation. Our predictive score for COVID-19 lethality included age ≥ 65 years,
40 diabetes, early-onset diabetes, obesity, age < 40 years, CKD, hypertension, pregnancy and
41 immunosuppression and significantly discriminates lethal from non-lethal COVID-19 cases (c-
42 statistic=0.830).

43 **RESULTS:** Here, we propose a mechanistic approach to evaluate risk for complications and
44 lethality attributable to COVID-19 considering the effect of obesity and diabetes in Mexico.
45 Our score offers a clinical tool for quick determination of high-risk susceptibility patients in a
46 first contact scenario.

47

48 **Keywords:** COVID-19; SARS-CoV-2; Diabetes; Obesity, Lethality; Mexico

49 INTRODUCTION

50 The first cases of SARS-CoV-2 infection in Mexico were reported at the end of February [1];
51 since then, the number of COVID-19 cases have been steadily increasing, with most fatal
52 cases being associated with the presence of comorbidity and, particularly, cardiometabolic
53 comorbidities. A high prevalence of cardiometabolic diseases worldwide represents a
54 challenge during the COVID-19 epidemic. An elevated number of patients with SARS-CoV-2
55 infection have a preexisting disease such as obesity, hypertension, cardiovascular disease,
56 diabetes, chronic respiratory disease or cancer [2,3]. Diabetes mellitus and obesity represent
57 a large share of the cardiometabolic morbidity burden of the region [4]; moreover, most cases
58 of diabetes remain either undiagnosed or lack adequate glycemic control, posing them at risk
59 of increased COVID-19 severity. Despite several reports evaluating the burden of
60 comorbidities including obesity, diabetes and hypertension on the clinical course of COVID-
61 19, the joint role of obesity and diabetes in modifying COVID-19 outcomes has not been fully
62 explored [5].

63 Several studies have demonstrated a higher susceptibility to acute respiratory infectious
64 diseases in people with diabetes [6]. Moreover, diabetes and obesity have been described as
65 independent risk factors for severe pulmonary infection [7,8]. Obesity influences the clinical
66 outcomes during an acute severe respiratory distress syndrome (ASRDS); it has been
67 proposed as a protective factor for mortality following lung injury (due to reverse causality) or
68 as a cause of mortality and adverse clinical outcomes for severe influenza cases (due to
69 mechanical and immunologic factor). In the cases of the COVID-19 outbreak, obesity has
70 been consistently associated with adverse outcomes [9,10]. Furthermore, a large proportion
71 of obesity cases in Mexico lives in geographical areas of increased social vulnerability, which
72 poses a structural inequality that might also increase mortality for COVID-19 associated to
73 both diabetes and obesity [11]. Chronic inflammation in obesity might worsen the acute
74 inflammatory response triggered by SARS-Cov2 infection, which might be associated to a

75 cytokine release syndrome [5,12]. Here, we investigate the role of both diabetes and obesity
76 in determining propensity for SARS-CoV-2 infection and its associated clinical outcomes
77 including disease severity and COVID-19 lethality; using these associations, we further
78 construct a clinically useful predictive model for COVID-19 mortality using national
79 epidemiological surveillance data from Mexico.

80 **METHODS**

81 Data sources

82 We extracted this dataset from the General Directorate of Epidemiology of the Mexican
83 Ministry of Health, which is an open-source dataset comprising daily updated data of
84 suspected COVID-19 cases which have been confirmed with a positive test for SARS-CoV-2
85 certified by the National Institute for Diagnosis and Epidemiological Referral [13].

86 Definitions of suspected and confirmed COVID-19 cases

87 The Ministry of Health defines a suspected COVID-19 case as an individual of any age whom
88 in the last 7 days has presented cough, fever or headache (at least two), accompanied by
89 either dyspnea, arthralgias, myalgias, sore throat, rhinorrhea, conjunctivitis or chest pain.
90 Amongst these suspected cases, the Ministry of Health establishes two protocols for case
91 confirmation: 1) SARS-CoV-2 testing is done widespread for suspected COVID-19 cases with
92 severe acute respiratory infection with signs of breathing difficulty or deaths in suspected
93 COVID-19 cases, 2) for all other suspected cases, a sentinel surveillance model is being
94 utilized, whereby 475 health facilities comprise a nationally representative sample which
95 samples ~10% of mild outpatient cases and all suspected severe acute respiratory infection
96 [14]. Demographic and health data are collected and uploaded to the epidemiologic
97 surveillance database by personnel from the corresponding individual facility.

98 Variables definitions

99 Available information for all confirmed, negative and suspected COVID-19 cases includes
100 age, sex, nationality, state and municipality where the case was detected, immigration status

101 as well as identification of individuals who speak indigenous languages from Mexico. Health
102 information includes status of diabetes, obesity, chronic obstructive pulmonary disease
103 (COPD), immunosuppression, pregnancy, arterial hypertension, cardiovascular disease,
104 chronic kidney disease (CKD) and asthma. Date of symptom onset, hospital admission and
105 death are available for all cases as well as treatment status (outpatient or hospitalized),
106 information regarding diagnosis of pneumonia, ICU admission and whether the patient
107 required invasive mechanical ventilation.

108 Statistical analysis

109 *Comorbidities associated to SARS-CoV-2 positivity*

110 We investigated the association of demographic and health data associated with SARS-CoV-
111 2 positivity using logistic regression analyses, excluding individuals who were only suspected
112 but unconfirmed cases of COVID-19. Next, we stratified these analyses for individuals with
113 only diabetes or only obesity to identify specific risk factors within these populations,
114 especially focusing on individuals who were <40 years and likely acquired the disease early.

115 *COVID-19 mortality risk*

116 In order to investigate risk factors predictive of COVID-19 related 30-day lethality, we fitted
117 Cox Proportional risk regression models estimating time from symptom onset up to death or
118 censoring, whichever occurred first in cases with confirmed positivity for SARS-CoV-2. To
119 identify diabetes and obesity-specific risk factors, we carried out stratified analyses. Given the
120 availability of SARS-CoV2 negative cases within the dataset, we fitted Cox models for 30-day
121 mortality which included SARS-CoV-2 positivity as an interaction term with different
122 comorbidities, hypothesizing that some factors increase mortality risk specifically for COVID-
123 19. Finally, we fitted a logistic regression model only for mortality cases to evaluate
124 associations with lethality rates in COVID-19 related and non-related deaths.

125 *Influence of obesity and diabetes in COVID-19 related outcomes*

126 Finally, we estimated factors associated to admission to hospital facilities, intensive care units
127 (ICUs) and requirements for mechanical ventilation in all confirmed COVID-19 cases using
128 logistic regression. To identify specific factors for all COVID-19 and non-COVID-19 patients
129 related to outcomes, we included interaction effects with comorbidities factors; we also
130 performed Kaplan-Meier analyses to identify the role of comorbidities in modifying lethality
131 risk in individuals with diabetes and obesity and compared across categories using Breslow-
132 Cox tests. Finally, we performed causal-mediation analyses with causally-ordered mediators
133 using a previously validated approach to investigate whether obesity mediates the decreases
134 COVID-19 survival attributable to diabetes, particularly in early-onset cases <40 years [15].

135 *Mechanistic mortality risk score for COVID-19*

136 Finally, we constructed a clinically useful model to predict 30-day mortality in COVID-19
137 cases that might be useful to apply in primary care facilities, including variables and
138 interactions which were identified in mortality analyses. Points were assigned by
139 standardizing all β coefficients with the minimum absolute β coefficient obtained from Cox
140 regression. Points were stratified according to categories of Low risk (≤ 0), Mild risk (1-3),
141 Moderate risk (4-6), High risk (7-9) and very high risk (≥ 10). Risk across categories was
142 verified using Kaplan-Meier analyses. C-statistics and D_{xy} values were corrected for over-
143 optimism using k-fold cross-validation (k=10) using the *rms* R package. A p-value <0.05 was
144 considered as statistical significance threshold. All analyses were performed using R software
145 version 3.6.2.

146 **RESULTS**

147 *COVID-19 cases in Mexico*

148 At the time of writing this report (April 27th, 2020), a total of 71,103 subjects had been treated
149 initially as suspected COVID-19 cases. Amongst them, 15,529 had been confirmed with as
150 positive and 46,079 tested negatives for SARS-CoV-2 infection; additionally, 8,477 cases
151 were still being studied as suspected cases pending testing reports. Amongst confirmed

152 cases, 1,434 deaths were reported (9.2%) whilst 881 deaths were SARS-CoV-2 negative
153 cases (1.9%) and 137 deaths of suspected but unconfirmed cases (1.6%) had been reported.
154 Compared to SARS-CoV-2 negative cases, confirmed cases were older, predominantly male
155 (1.35:1 ratio), had higher rates of hospitalization and showed a higher prevalence of diabetes,
156 hypertension and obesity, but less CKD. SARS-CoV-2 cases were also more likely to be
157 treated as inpatients and had higher rates of ICU admission and requirements for invasive
158 ventilation compared to negative cases (**Table 1**).

159 *Factors associated with COVID-19 positivity*

160 We investigated cases related to COVID-19 positivity within Mexico. We found that risk of
161 SARS-CoV-2 positivity was higher with diabetes, hypertension, COPD, immunosuppression,
162 CKD, obesity, age >65 and male sex (**Supplementary Figure 1**). When assessing age, we
163 observed reduced odds of SARS-CoV-2 positivity in patients younger than age 40 and, in
164 contrast, when exploring its interaction with diabetes, we observed an increased probability of
165 SARS-CoV-2 infection. In stratified models, we observed that for patients with diabetes,
166 SARS-CoV-2 positivity was associated with obesity, male sex and an interaction effect was
167 observed between obesity and having less than 40 years; for patients with obesity, diabetes
168 and male sex were also significant.

169 *Predictors for COVID-19 related 30-day mortality*

170 We identified that COVID-19 cases were associated with a near four-fold increase in mortality
171 due to acute respiratory infection (HR 3.864, 95%CI 3.501-4.264) compared to non-COVID-
172 19 cases. Of interest, the only comorbidity which conferred increased lethality risk exclusively
173 for COVID-19 compared to non-COVID-19 was obesity (HR 1.567, 95%CI 1.273-1.928,
174 **Figure 1A**). Factors associated to increased lethality in COVID-19 cases were age >65
175 years, diabetes mellitus, obesity, CKD, COPD, immunosuppression and hypertension (**Figure**
176 **1B**). We searched for an interaction between diabetes mellitus and age <40 years adjusted

177 for sex and obesity; a higher mortality risk was found for early onset diabetes cases (HR
178 2.764, 95%CI 1.718-4.447).

179 *COVID-19 in patients with diabetes mellitus*

180 Confirmed COVID-19 cases with diabetes had a mean age of 56.9 (\pm 12.9) years and were
181 predominantly male. This population had particularly higher mortality rate (10.0% vs. 1.6%),
182 hospitalization and confirmed pneumonia compared with those without diabetes. When
183 stratifying mortality for those with early onset diabetes (<40 years) had higher mortality rates
184 compared to individuals <40 years without diabetes (17.1% vs. 4.6%); similarly, those aged
185 >65 years had lower rates compared to those <65 years with diabetes (23.8% vs. 29.7%). As
186 expected, obesity, hypertension, COPD, CKD, CVD, immunosuppression and asthma were
187 also more prevalent in this population. Interestingly, we observed no significant differences in
188 ICU admission and requirements for mechanical ventilation between subjects with and
189 without diabetes (**Supplementary table 1**). In patients with diabetes mellitus, COVID-19
190 related mortality was higher in those with concomitant immunosuppression, COPD, CKD and
191 those aged >65 years (**Figure 1C**). When assessing the role of comorbidities, COVID-19
192 patients with diabetes, coexistent obesity, those with early onset diabetes (<40 years) or an
193 increase in the number of comorbidities had increased risk of COVID-19 lethality (Breslow
194 test $p < 0.001$, **Figure 2**). When comparing cases with and without COVID-19 amongst
195 patients with diabetes mellitus, only obesity displayed a significant interaction with COVID-19
196 (HR 1.449 95%CI 1.071-1.960) with diabetes after adjustment for age, sex and comorbidities
197 (**Supplementary Figure 2**).

198 *COVID-19 in patients with obesity*

199 Similar to patients with diabetes, confirmed COVID-19 cases with obesity had particularly
200 higher rates of mortality (13.6% vs. 8.17%), hospitalization and confirmed pneumonia.
201 Furthermore, patients with obesity also had higher rates of ICU admission (13.2% vs. 10.5%)
202 and were more likely to be intubated (13.1% vs. 10.3%). As expected, diabetes,

203 hypertension, COPD, smoking, CVD and asthma were also more prevalent in patients with
204 obesity (**Supplementary table 2**). As previously mentioned, obesity was identified as a risk
205 factor which displayed differential risk for COVID-19 infection, specific risk factors for lethality
206 in obese patients with COVID-19 infection immunosuppression and age >65 (**Figure 1D**);
207 overall, COVID-19 increased risk of mortality in obesity nearly six-fold (HR 5.954, 95%CI
208 4.939-7.178). The addition of obesity to any number of comorbidities significantly increased
209 the risk for COVID-19 lethality (Breslow test $p < 0.001$, **Figure 2-C**). Using causally ordered
210 mediation analysis we investigated whether the effect of diabetes (E) on COVID-19 related
211 lethality was partially mediated by obesity (M); the direct effect of diabetes on COVID-19
212 lethality was significant ($\Delta_{E \rightarrow Y} = 1.72$, 95%CI 1.54-1.93) as was the indirect effect of obesity
213 ($\Delta_{M \rightarrow Y} = 1.44$, 95%CI: 1.32-1.58), representing 45.5% of the total effect of diabetes.

214 *COVID-19 outcomes and comorbidities*

215 Given the increased risk of diabetes and obesity in modifying COVID-19 related lethality, a
216 secondary objective of our study was to investigate its associations with inpatient outcomes,
217 including hospitalization rate, ICU admission and requirement for mechanical ventilation. In
218 general, early-onset diabetes patients and those with obesity had higher risk of
219 hospitalization, whilst patients with obesity also had increased risk for ICU admission and
220 required intubation. Patients with diabetes mellitus overall had higher risk of hospitalization
221 with no significant additional risk of ICU admission and intubation (**Figure 3**).

222 *Mechanistic score for mortality in COVID-19*

223 Using the identified predictors for mortality and the observed interaction for early-onset
224 diabetes, we designed a predictive score for COVID-19 mortality using Cox regression using
225 a random split of 80% of the dataset stratified by mortality (n=12,424, deaths=1,137). We
226 identified as significant predictors age >65 years, diabetes mellitus, obesity, CKD, COVID-19
227 related pneumonia, COPD, pregnancy and immunosuppression (**Table 2**); age <40 was a
228 protective factor which was modified by its interaction with T2D ($R^2 = 0.160$, C-statistic 0.828,

229 $D_{xy}=0.656$); assigning the point system did not significantly reduce the model's performance
230 ($R^2=0.159$, C-statistic=0.829, $D_{xy}=0.657$). Finally, category stratification reduced only
231 moderately performance statistics ($R^2=0.157$, C-statistic=0.816, $D_{xy}=0.631$), and were not
232 significantly modified after cross-validation correction ($R^2=0.182$, $D_{xy}=0.657$). The score was
233 then validated using the remaining 20% of the population ($n=3,105$, deaths=297); we
234 observed that the score retained its predictive and discriminative ability ($R^2=0.141$, C-
235 statistic=0.801, $D_{xy}=0.602$) as did the categories ($R^2=0.144$, C-statistic=0.792, $D_{xy}=0.585$).
236 Distribution of the score significantly discriminates between lethal and non-lethal COVID-19
237 cases (**Figure 4**).

238 **DISCUSSION**

239 Our results demonstrate that diabetes, particularly early onset diabetes mellitus, obesity and
240 comorbidity burden modify risk profiles in patients with COVID-19 infection in Mexico and
241 significantly improve mortality prediction related to COVID-19 lethality. These findings
242 position the notion that early-onset type 2 diabetes might carry a higher risk of mortality in
243 younger patients, which is similar to older patients with comorbidities and only higher in older
244 patients with diabetes. Furthermore, our results suggest that obesity is a COVID-19 specific
245 risk factor for mortality, risk of ICU admission, tracheal intubation and hospitalization and
246 even increases risk in patients with diabetes and COVID-19 infection. Overall, this positions
247 the co-existence of obesity and diabetes, particularly early-onset diabetes, as a considerable
248 risk factor for COVID-19 mortality in Mexicans, whom have reported an alarmingly high
249 burden of both conditions in recent health surveys.

250 The relationship between increased risk of mortality attributable to acute severe respiratory
251 infections in patients with diabetes mellitus has been extensively reported, particularly for the
252 acute respiratory syndrome caused by SARS-CoV-1 [16–18]. Evidence relating SARS-CoV-2
253 infections in China demonstrated increased rates of diabetes mellitus in hospitalized patients
254 and in those with increased disease severity as assessed by ICU admission and requirement

255 for invasive ventilation. Additionally, hospitalized patients have shown increased rates of both
256 obesity and diabetes for COVID-19 compared to non-hospitalized cases in the US, China and
257 Italy [5,19,20]. Increased susceptibility for COVID-19 in patients with diabetes may be
258 explained for several potential mechanisms including an increased lung ACE2 expression
259 and elevated circulating levels of furin, a protease involved in viral entry to cells, and a
260 decreased clearance of SARS-CoV-2 viral particles in subjects with diabetes and/or
261 hypertension associated with ACE2 expression [21–24]. Impairments in immunity observed in
262 patients with diabetes are characterized by initial delay in activation of Th1 cell-mediated
263 immunity and late hyper-inflammatory response and are consistent with the increased risk
264 associated with additional immunosuppression observed with our data [25]. Additional factors
265 which have been proposed to modify COVID-19 mortality risk and worsen glycemic control in
266 diabetes include corticosteroid therapy, inadequate glucose monitoring, the effect of social
267 distancing on diabetes care and the use of antihypertensive medication; however these
268 factors remain to be confirmed by clinical evidence [26]. Given the large proportion of
269 undiagnosed diabetes cases in Mexican and poor glycemic control reported by recent
270 estimates, the burden of COVID-19 might be higher than expected in Mexico and poses a
271 challenge for the Mexican healthcare system to give particular attention to this sector as the
272 epidemic moves forward [27–29].

273 Diabetes mellitus is one of the main causes of morbidity and it accounts for a large proportion
274 of mortality risk in Mexican population [4]. Of relevance, Mexicans have increased risk of
275 diabetes and diabetes-related obesity attributable to genetic variants associated to its
276 Amerindian ancestry, and an earlier age of onset independent of body-mass index [30,31].
277 Data on the incidence of early-onset type 2 diabetes in Mexican population position obesity
278 and insulin resistance as significant risk factors, which are also highly prevalent in younger
279 patients and increase metabolic risk [32,33]. These associations partly explain the increased
280 risk of COVID-19 lethality in younger patients within our cohort despite the younger average

281 age of Mexican population and poses early-onset diabetes mellitus as a significant risk factor
282 for COVID-19 mortality and increased severity of infection in younger patients [5,34].
283 In our work, we demonstrate that compared to non-COVID-19 infections, obesity significantly
284 modifies the risk of mortality attributable to COVID-19 infection. Obesity and, in particular,
285 abdominal obesity, is one of Mexico's main public health problems; in recent years the socio-
286 economic burden of obesity as well as its impact on mortality have increased drastically, with
287 the Ministry of Health declaring a state of epidemiological emergency [35]. Evidence from
288 different regions has supported the notion that obesity increases mortality risk and severity of
289 COVID-19 infections, which holds particularly true for younger patients [2,36]. Obesity is
290 characterized by a low-grade state of inflammation and may impair immune response which
291 in turn also may affect the lung parenchyma, increasing the risk for inflammatory lung
292 diseases [37,38]. In particular, abdominal obesity reduces the compliance of lung, chest wall
293 and entire respiratory system, resulting in impaired ventilation of the base of the lungs and
294 reduced oxygen saturation of blood [39]. Recently, Simonnet et al. explored the high
295 prevalence of obesity in patients with COVID-19 reporting that obesity is a risk factor for
296 SARS-CoV-2 infection severity independent of age, diabetes and hypertension. Notably,
297 ACE2 expression in adipose tissue is higher than in the lung and its expression profile is not
298 different in obese and non-obese subjects; however, obese subjects have more adipocytes;
299 thus, they have a greater number of ACE2-expressing cells and thus higher likelihood of
300 SARS-CoV-2 entry [2,40]. Our data shows that obesity is a specific risk factor for COVID-19
301 related outcomes and that it partly mediates the risk associated with diabetes mellitus. Public
302 health efforts by the Mexican government in epidemiological surveillance have largely
303 focused in identifying patient's at highest risk of complications; these findings could inform
304 public health decisions and increase awareness on the role of obesity in modifying risk of
305 COVID-18 outcomes.

306 Our study had some strengths and limitations. First, we analyzed a large dataset which
307 included information on both confirmed positive and negative SARS-CoV-2 cases, which
308 provides a unique opportunity to investigate COVID-19 specific risk factors and develop a
309 predictive model for COVID-19 mortality. Additionally, with the database being nationally-
310 representative it allows for reasonable estimates on the impact of both diabetes and obesity
311 despite the possibility of important regional differences in cardiometabolic risk which might
312 influence risk estimates. A potential limitation of this study is the use of data collected from a
313 sentinel surveillance system model, which is skewed towards investigating high risk cases or
314 only those with specific risk factors which on one hand increases power to detect the effect of
315 comorbidities and on the other hand might not be representative of milder cases of the
316 disease; this is demonstrated in the risk of COVID-19 positivity, which is higher for high risk
317 cases. The updating daily estimates of COVID-19 cases are unlikely to change the direction
318 of the identified associations though it might modify numeric estimates. Implementation of our
319 proposed model might be useful to allocate prompt responses to high risk cases and improve
320 stratification of disease severity.

321 In conclusion, we show that both diabetes and obesity increase the risk of SARS-CoV-2
322 infection in Mexico. In particular, diabetes increases the risk of COVID-19 related mortality
323 and, specifically, increases mortality risk in early-onset cases. Obesity is a COVID-19 specific
324 risk factor for mortality and for increased disease severity; obesity also is a partial mediator
325 on the effect of diabetes in decreasing survival associated with COVID-19 infection. This
326 mechanistic interpretation on the risk of comorbidities allowed the development of a model
327 with good performance to predict mortality in COVID-19 cases. Given the burden of obesity
328 and diabetes in Mexico, COVID-19 lethality might be higher in younger cases. Special
329 attention should be given to susceptible individuals and screening should be conducted for all
330 symptomatic cases with either obesity and/or diabetes to decrease the burden associated
331 with COVID-19 in Mexico.

332 **Conflict of interest:** Nothing to disclose.

333 **Role of the funding source:** This research received no funding.

334 **ACKNOWLEDGMENTS**

335 JPBL, AVV, NEAV, AMS and CAFM are enrolled at the PECCEM program of the Faculty of
336 Medicine at UNAM. JPBL and AVV are supported by CONACyT. The authors would like to
337 acknowledge the invaluable work of all of Mexico's healthcare community in managing the
338 COVID-19 epidemic. Its participation in the COVID-19 surveillance program has made this
339 work a reality, we are thankful for your effort.

340 **DATA AVAILABILITY**

341 All data sources and R code are available for reproducibility of results at
342 https://github.com/oyaxbell/covid_diabetesmx.

343 **AUTHOR CONTRIBUTIONS**

344 Research idea and study design OYBC, JPBL, CAAS; data acquisition: OYBC, AGD; data
345 analysis/interpretation: OYBC, JPBL, NEAV, AVV, AGD, JJN, CAAS; statistical analysis:
346 OYBC, NEAV; manuscript drafting: OYBC, NEAV, AVV, JPBL, AMS, CAFM, JJN; supervision
347 or mentorship: OYBC, CAAS. Each author contributed important intellectual content during
348 manuscript drafting or revision and accepts accountability for the overall work by ensuring
349 that questions pertaining to the accuracy or integrity of any portion of the work are
350 appropriately investigated and resolved.

351 **FUNDING:** No funding was received.

352 **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.

353 **REFERENCES**

- 354 1. Información Internacional y Nacional sobre nuevo Coronavirus (COVID-2019) |
355 Secretaría de Salud | Gobierno | gob.mx [Internet]. [cited 19 Apr 2020]. Available:
356 [https://www.gob.mx/salud/documentos/informacion-internacional-y-nacional-sobre-](https://www.gob.mx/salud/documentos/informacion-internacional-y-nacional-sobre-nuevo-coronavirus-2019-ncov)
357 [nuevo-coronavirus-2019-ncov](https://www.gob.mx/salud/documentos/informacion-internacional-y-nacional-sobre-nuevo-coronavirus-2019-ncov)

- 358 2. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High
359 prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-
360 2) requiring invasive mechanical ventilation. *Obesity (Silver Spring)*. 2020;
361 doi:10.1002/oby.22831
- 362 3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
363 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
364 study. *Lancet*. 2020;395: 1054–1062. doi:10.1016/S0140-6736(20)30566-3
- 365 4. Bello-Chavolla OY, Rojas-Martinez R, Aguilar-Salinas CA, Hernández-Avila M.
366 Epidemiology of diabetes mellitus in Mexico. *Nutr Rev*. 2017;75: 4–12.
367 doi:10.1093/nutrit/nuw030
- 368 5. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline
369 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to
370 ICUs of the Lombardy Region, Italy. *JAMA*. 2020; doi:10.1001/jama.2020.5394
- 371 6. Muller LMAJ, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AIM, et al.
372 Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.
373 *Clin Infect Dis*. 2005;41: 281–288. doi:10.1086/431587
- 374 7. Van Kerkhove MD, Vandemaele KAH, Shinde V, Jaramillo-Gutierrez G, Koukounari A,
375 Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1)
376 infection: a global pooled analysis. *PLoS Med*. 2011;8: e1001053.
377 doi:10.1371/journal.pmed.1001053
- 378 8. Luzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for
379 COVID-19 pandemic. *Acta Diabetol*. 2020; doi:10.1007/s00592-020-01522-8
- 380 9. Jose RJ, Manuel A. Does COVID-19 Disprove the Obesity Paradox in ARDS? *Obesity*
381 (Silver Spring). 2020; doi:10.1002/oby.22835
- 382 10. Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. *Obesity*
383 (Silver Spring). 2020; doi:10.1002/oby.22818

- 384 11. Shamah-Levy T, Campos-Nonato I, Cuevas-Nasu L, Hernández-Barrera L, Morales-
385 Ruán MDC, Rivera-Dommarco J, et al. [Overweight and obesity in Mexican vulnerable
386 population. Results of Ensanut 100k]. *Salud Publica Mex.* 2019;61: 852–865.
387 doi:10.21149/10585
- 388 12. Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. *Science.* 2020;
389 eabb8925. doi:10.1126/science.abb8925
- 390 13. Datos Abiertos - Dirección General de Epidemiología | Secretaría de Salud | Gobierno |
391 gob.mx [Internet]. [cited 18 Apr 2020]. Available:
392 <https://www.gob.mx/salud/documentos/datos-abiertos-152127?idiom=es>
- 393 14. Secretaría de Salud Subsecretaría de Prevención y Promoción de la Salud Dirección
394 General de Epidemiología. LINEAMIENTO ESTANDARIZADO PARA LA VIGILANCIA
395 EPIDEMIOLÓGICA Y POR LABORATORIO DE LA ENFERMEDAD RESPIRATORIA
396 VIRAL. Apr 1, 2020.
- 397 15. Cho S-H, Huang Y-T. Mediation analysis with causally ordered mediators using Cox
398 proportional hazards model. *Stat Med.* 2019;38: 1566–1581. doi:10.1002/sim.8058
- 399 16. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and
400 diabetes are independent predictors for mortality and morbidity in patients with SARS.
401 *Diabet Med.* 2006;23: 623–628. doi:10.1111/j.1464-5491.2006.01861.x
- 402 17. Bello-Chavolla OY, Bahena-Lopez JP, Garciadiego-Fosass P, Volkow P, Garcia-Horton
403 A, Velazquez-Acosta C, et al. Bloodstream infection caused by *S. aureus* in patients
404 with cancer: a 10-year longitudinal single-center study. *Support Care Cancer.* 2018;26:
405 4057–4065. doi:10.1007/s00520-018-4275-1
- 406 18. Akbar DH. Bacterial pneumonia: comparison between diabetics and non-diabetics. *Acta*
407 *Diabetol.* 2001;38: 77–82. doi:10.1007/s005920170017
- 408 19. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected
409 Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United

- 410 States, February 12-March 28, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69: 382–
411 386. doi:10.15585/mmwr.mm6913e2
- 412 20. Liang W-H, Guan W-J, Li C-C, Li Y-M, Liang H-R, Zhao Y, et al. Clinical characteristics
413 and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and
414 outside Hubei (non-epicenter): A Nationwide Analysis of China. *Eur Respir J.* 2020;
415 doi:10.1183/13993003.00562-2020
- 416 21. Chen X, Hu W, Ling J, Mo P, Zhang Y, Jiang Q, et al. Hypertension and Diabetes Delay
417 the Viral Clearance in COVID-19 Patients. *medRxiv.* 2020;
418 doi:10.1101/2020.03.22.20040774
- 419 22. Rao S, Lau A, So H-C. Exploring diseases/traits and blood proteins causally related to
420 expression of ACE2, the putative receptor of 2019-nCov: A Mendelian Randomization
421 analysis. *medRxiv.* 2020; doi:10.1101/2020.03.04.20031237
- 422 23. Fernandez C, Rysä J, Almgren P, Nilsson J, Engström G, Orho-Melander M, et al.
423 Plasma levels of the proprotein convertase furin and incidence of diabetes and
424 mortality. *J Intern Med.* 2018;284: 377–387. doi:10.1111/joim.12783
- 425 24. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM
426 structure of the 2019-nCoV spike in the prefusion conformation. *Science.* 2020;367:
427 1260–1263. doi:10.1126/science.abb2507
- 428 25. Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological
429 mechanisms contributing to the double burden of diabetes and intracellular bacterial
430 infections. *Immunology.* 2015;144: 171–185. doi:10.1111/imm.12394
- 431 26. Klonoff DC, Umpierrez GE. COVID-19 in patients with diabetes: risk factors that
432 increase morbidity. *Metab Clin Exp.* 2020; 154224. doi:10.1016/j.metabol.2020.154224
- 433 27. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence,
434 pathophysiology, prognosis and practical considerations. *Diabetes Metab Syndr.*
435 2020;14: 303–310. doi:10.1016/j.dsx.2020.04.004

- 436 28. Campos-Nonato I, Ramírez-Villalobos M, Flores-Coria A, Valdez A, Monterrubio-Flores
437 E. Prevalence of previously diagnosed diabetes and glycemic control strategies in
438 Mexican adults: ENSANUT-2016. PLoS One. 2020;15: e0230752.
439 doi:10.1371/journal.pone.0230752
- 440 29. Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A
441 statement from the European Society of Endocrinology. Endocrine. 2020;
442 doi:10.1007/s12020-020-02294-5
- 443 30. SIGMA Type 2 Diabetes Consortium, Williams AL, Jacobs SBR, Moreno-Macías H,
444 Huerta-Chagoya A, Churchhouse C, et al. Sequence variants in SLC16A11 are a
445 common risk factor for type 2 diabetes in Mexico. Nature. 2014;506: 97–101.
446 doi:10.1038/nature12828
- 447 31. Almeda-Valdes P, Gómez Velasco DV, Arellano Campos O, Bello-Chavolla OY, Del
448 Rocío Sevilla-González M, Viveros Ruiz T, et al. The SLC16A11 risk haplotype is
449 associated with decreased insulin action, higher transaminases and large-size
450 adipocytes. Eur J Endocrinol. 2019;180: 99–107. doi:10.1530/EJE-18-0677
- 451 32. Arellano-Campos O, Gómez-Velasco DV, Bello-Chavolla OY, Cruz-Bautista I,
452 Melgarejo-Hernandez MA, Muñoz-Hernandez L, et al. Development and validation of a
453 predictive model for incident type 2 diabetes in middle-aged Mexican adults: the
454 metabolic syndrome cohort. BMC Endocr Disord. 2019;19: 41. doi:10.1186/s12902-
455 019-0361-8
- 456 33. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, García E, Valles V, Ríos-Torres JM, et
457 al. Prevalence and characteristics of early-onset type 2 diabetes in Mexico. Am J Med.
458 2002;113: 569–574. doi:10.1016/s0002-9343(02)01314-1
- 459 34. Jiménez-Corona A, Rojas R, Gómez-Pérez FJ, Aguilar-Salinas CA. Early-onset type 2
460 diabetes in a Mexican survey: results from the National Health and Nutrition Survey

- 461 2006. *Salud Publica Mex.* 2010;52 Suppl 1: S27–35. doi:10.1590/s0036-
462 36342010000700006
- 463 35. Nieto C, Tolentino-Mayo L, Monterrubio-Flores E, Medina C, Patiño SR-G, Aguirre-
464 Hernández R, et al. Nutrition Label Use Is Related to Chronic Conditions among
465 Mexicans: Data from the Mexican National Health and Nutrition Survey 2016. *J Acad*
466 *Nutr Diet.* 2019; doi:10.1016/j.jand.2019.07.016
- 467 36. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in
468 patients younger than 60 years is a risk factor for Covid-19 hospital admission. *Clin*
469 *Infect Dis.* 2020; doi:10.1093/cid/ciaa415
- 470 37. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. *Int J Obes.*
471 2013;37: 333–340. doi:10.1038/ijo.2012.62
- 472 38. Zhang X, Zheng J, Zhang L, Liu Y, Chen GP, Zhang HP, et al. Systemic inflammation
473 mediates the detrimental effects of obesity on asthma control. *Allergy Asthma Proc.*
474 2017; doi:10.2500/aap.2017.38.4096
- 475 39. Dixon AE, Peters U. The effect of obesity on lung function. *Expert Rev Respir Med.*
476 2018;12: 755–767. doi:10.1080/17476348.2018.1506331
- 477 40. Jia X, Yin C, Lu S, Chen Y, Liu Q, Bai J, et al. Two Things about COVID-19 Might Need
478 Attention. 2020; doi:10.20944/preprints202002.0315.v1
- 479

480 **Table 1.** Descriptive statistics comparing negative, positive and suspected cases for SARS-CoV-2 in Mexico at 04/27/2020.

481 *Abbreviations:* ICU= intense care unit; COPD= chronic obstructive pulmonary disease; CKD= chronic kidney disease; CVD=
 482 cardiovascular disease.

Parameter	Positive for SARS-CoV-2 n=15529	Negative for SARS-CoV-2 n=46960	Suspected for SARS-CoV-2 n=8614
Age (mean ± sd)	46.55±15.51	39.56±17.9	43.22±17.27
Male sex (%)	8977(57.8)	21955(46.8)	4664(54.1)
Mortality (%)	1434(9.2)	881(1.9)	137(1.6)
Hospitalization (%)	6042(38.9)	9974(21.2)	2607(30.3)
Pneumonia (%)	4588(29.5)	6341(13.5)	1841(21.4)
ICU admission (%)	676(4.4)	774(1.6)	211(2.4)
Invasive ventilation (%)	669(4.3)	598(1.3)	197(2.3)
Diabetes (%)	2831(18.2)	5163(11)	1323(15.4)
COPD (%)	389(2.5)	1330(2.8)	214(2.5)
Asthma (%)	542(3.5)	2571(5.5)	337(3.9)
Immunosuppression (%)	296(1.9)	1402(3)	183(2.1)
Hypertension (%)	3370(21.7)	7353(15.7)	1611(18.7)

Parameter	Positive for SARS-CoV-2	Negative for SARS-CoV-2	Suspected for SARS-CoV-2
	n=15529	n=46960	n=8614
Obesity (%)	3215(20.7)	6570(14)	1532(17.8)
CKD (%)	359(2.3)	1130(2.4)	262(3)
CVD (%)	453(2.9)	1610(3.4)	267(3.1)
Smoking (%)	1374(8.8)	4835(10.3)	811(9.4)

483

484

485 **Table 2.** Cox proportional risk models for lethality using the mechanistic COVID-19 lethality score in confirmed cases of COVID-19
 486 using individual components, single score point and risk stratification categories. Abbreviations: COPD= chronic obstructive
 487 pulmonary disease; CKD= chronic kidney disease; CVD= cardiovascular disease.


Model	Parameter	B	Score	SE	Wald	HR	95% CI	P value
Individual variables <i>C-statistic= 0.828</i>	Age ≥65 years	0.753	3	0.065	11.568	2.12	1.87-2.41	<0.001
	Pregnancy	0.963	4	0.451	2.133	2.62	1.08-6.35	0.033
	Diabetes	0.251	1	0.066	3.802	1.29	1.13-1.46	<0.001
	Diabetes*Age <40 years	1.092	4	0.265	4.119	2.98	1.77-5.01	<0.001
	Age <40 years	-1.397	-6	0.136	-10.283	0.25	0.19-0.32	<0.001
	Obesity	0.374	1	0.066	5.680	1.45	1.28-1.65	<0.001
	Pneumonia	1.697	7	0.072	23.444	5.46	4.74-6.29	<0.001

	CKD	0.568	2	0.120	4.179	1.76	1.39-2.23	<0.001
	COPD	0.277	1	0.117	2.361	1.32	1.05-1.66	0.018
	Immunosuppression	0.500	2	0.137	3.365	1.65	1.26-2.16	<0.001
<hr/>								
Score point training	1-Point increment	0.246		0.007	36.15	1.28	1.26-1.30	<0.001
	<i>C-statistic= 0.829</i>							
<hr/>								
	Low-Risk (0 pts)				Reference			
Risk Categories	Mild-Risk (1-3 pts)	1.873		0.136	13.73	6.51	4.98-8.50	<0.001
training	Moderate-Risk (4-6 pts)	2.727		0.131	20.84	15.28	11.83-19.75	<0.001
	<i>C-statistic= 0.816</i>							
	High-Risk (7-9 pts)	3.287		0.125	26.38	26.76	20.96-34.16	<0.001
	Very High-Risk (≥10 pts)	3.824		0.131	29.07	45.78	35.38-59.25	<0.001

488


489

490 **FIGURE LEGENDS**



491
 492 **Figure 1.** Cox proportional risk regression analysis to evaluate lethality of SARS-CoV-2 in Mexico, compared to SARS-CoV2 negative
 493 cases for all suspected cases with SARS-CoV2 status available (A) and stratified by diabetes mellitus (B) and obesity (C).
 494 *Abbreviations:* ICU= intense care unit; COPD= chronic obstructive pulmonary disease; CKD= chronic kidney disease; CVD=
 495 cardiovascular disease, HR= Hazard ratio.

496




497

498 **Figure 2.** Kaplan-Meier survival curves to evaluate lethality of SARS-CoV-2 positivity in patients with diabetes and comorbidities (A),

499 diabetes and obesity (B), obesity and comorbidities (C) and diabetes with age 40 years (D). Abbreviations: DM= Diabetes

500 mellitus; OB= Obesity; Comorb= Comorbidities.

501




502

503

504

505

Figure 3. Logistic regression analyses to evaluate COVID-19 related outcomes in all patients with SARS-CoV2 positivity for admission to ICU (A), mechanical ventilation (B) and hospital admission risk (C).



506

507 **Figure 4.** Symptom onset among lethal and non-lethal cases in new-confirmed COVID 19 cases, stratified by diabetes and obesity

508 status (A), density histogram of scores of the mechanistic COVID-19 score (B). Points and score intervals considered for clinical

509 score scale (C) and Kaplan-Meier Survival analysis curves to evaluate lethality using risk categories in the training (D) and

510 validation cohorts (E). Abbreviations: OB= Obesity; DM= Diabetes mellitus; CKD= chronic kidney disease; COPD= Chronic

511 obstructive pulmonary disease.